Nanoco Regulatory News (NANO)

29 Jan 2007 07:01

Evolutec Group PLC29 January 2007 Monday 29 January 2007 Evolutec Group plc ("Evolutec" or "Company") Appointment of Numis Securities Limited As previously announced on 3 January 2007, the Board of Evolutec Group plc (AIM:EVC) is exploring all strategic options available to the Group in order torealise value for shareholders. The Board is pleased to announce the appointment, with immediate effect, ofNumis Securities Limited as nominated adviser and broker to assist in thisprocess. Shareholders will be kept up to date with developments as appropriate and, inany event, on announcement of the Annual Results of the Group which is due totake place on 27 February 2007. Enquiries: Evolutec 0118 922 4480Mark Carnegie Brown, Chief Executive OfficerNicholas Badman, Chief Financial Officerwww.evolutec.co.uk Numis 020 7776 1500Michael Meade Financial Dynamics 020 7831 3113David YatesBen Brewerton Notes for Editors: About Evolutec Evolutec, which is based in Reading, UK, is a clinical stage biopharmaceuticalcompany with a focus on allergy, inflammation and auto-immune diseases. rEV576, the Company's second product development candidate is a complementinhibitor which has demonstrated preclinical activity against the autoimmunediseases myasthenia gravis and Guillain-Barre Syndrome, asthma and acutemyocardial infarction ("AMI") (heart attack). Evolutec has established aresearch collaboration with Case Western Reserve University, Cleveland, Ohio, toundertake further preclinical work with rEV576 in myasthenia gravis. Evolutec is listed on the AIM market of the London Stock Exchange and developstherapeutics originally isolated from the saliva of ticks. The tick remainsundetected by its hosts, including humans, by injecting an array of moleculesinto the skin that suppresses host immunity. These stealth molecules haveundergone millions of years of natural evolution to select a promising efficacy,potency and safety profile. Evolutec employs the tick's evolutionary stealthtechnology to offer the potential of treating human diseases. This information is provided by RNS The company news service from the London Stock Exchange